NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
NeuroMetrix, Inc. (Nasdaq: NURO) has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroMetrix, Inc. (Nasdaq: NURO) has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell aims to enhance the company's DPNCheck® business, focusing on the Medicare Advantage market. DPNCheck is vital for screening diabetic peripheral neuropathy, a common diabetes complication. With over 20 years in sales and strategy, her experience is expected to drive growth. NeuroMetrix plans to launch its second-generation DPNCheck device, indicating a potential expansion in its value-based healthcare footprint.
Positive
- Appointment of Susan M. Bell as Senior VP, enhancing leadership in population health.
- Expansion focus on the Medicare Advantage market, a key growth area.
- DPNCheck's existing adoption by major Medicare Advantage plans suggests market confidence.
- Upcoming launch of the second-generation DPNCheck device may boost business growth.
Negative
- None.
Details
News Market Reaction – NURO
The recorded move for NURO in the trading session of this news was -2.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck® business with a primary focus on the Medicare Advantage population, and more broadly, expanding the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term complication of diabetes that may lead to foot ulcers and amputation.
Ms. Bell brings to the company over 20 years of sales, business development and strategy experience in the Medicare Advantage sector, and more generally in population health. Ms. Bell was most recently at eHealth, Inc., where she was Senior Director, Value Based Provider Partnerships. In this role, she was responsible for building partnerships with the largest and most innovative Medicare Advantage plans and at-risk provider networks. Prior to that role, Ms. Bell was Chief Growth Officer at Cecelia Health where she was responsible for building the company's chronic disease management business. Ms. Bell has also held senior roles at CareCentrix, Inc., ZeOmega, Inc., Bosch Healthcare, and VITAS Healthcare. She holds a Bachelor's degree in Nursing from the University of Manitoba and is licensed as a registered nurse.
"Sue's background in population health, and Medicare Advantage in particular, is ideally suited to our DPNCheck business. The technology already has initial adoption by some of the largest Medicare Advantage plans and we believe there is a substantial opportunity to grow and expand the business," said Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer. "We are excited to have someone with Sue's deep experience and energy join at this time, particularly as we are gearing up to launch our second generation DPNCheck device. I look forward to working with Sue to build on our success to date and to take the DPNCheck business to new heights."
About DPNCheck
DPNCheck is an automated, fast, accurate, and quantitative nerve conduction test used to evaluate peripheral neuropathies. It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor peripheral neuropathies. Please visit at www.dpncheck.com.
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit NeuroMetrix.com.
Source: NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.